Next Article in Journal
AQP2 Plasma Membrane Diffusion Is Altered by the Degree of AQP2-S256 Phosphorylation
Next Article in Special Issue
PPIC, EMP3 and CHI3L1 Are Novel Prognostic Markers for High Grade Glioma
Previous Article in Journal
A Clinical Trial about a Food Supplement Containing α-Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients
Previous Article in Special Issue
Golgi-Related Proteins GOLPH2 (GP73/GOLM1) and GOLPH3 (GOPP1/MIDAS) in Cutaneous Melanoma: Patterns of Expression and Prognostic Significance
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2016, 17(11), 1803;

The Expression and Clinical Outcome of pCHK2-Thr68 and pCDC25C-Ser216 in Breast Cancer

Department of Radiation Oncology, PLA Army General Hospital, Beijing 100700, China
Department of Oncology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China
Department of Emergency, Chinese PLA General Hospital, Beijing 100853, China
Radiologic Sciences and Respiratory Therapy Division, School of Health and Rehabilitation Sciences, The Ohio State University College of Medicine, Columbus, OH 43210, USA
These authors contributed equally to the work.
Authors to whom correspondence should be addressed.
Academic Editor: William Chi-shing Cho
Received: 2 July 2016 / Revised: 23 September 2016 / Accepted: 12 October 2016 / Published: 28 October 2016
(This article belongs to the Collection Advances in Molecular Oncology)
Full-Text   |   PDF [1586 KB, uploaded 31 October 2016]   |  


Checkpoint kinase 2 (CHK2) and cell division cycle 25C (CDC25C) are two proteins involved in the DNA damage response pathway, playing essential roles in maintaining genome integrity. As one of the major hallmarks of abnormal cellular division, genomic instability occurs in most cancers. In this study, we identified the functional expression of pCHK2-Thr68 and pCDC25C-Ser216 in breast cancer, as well as its association with breast cancer survival. Tissue microarray analysis using immunohistochemistry was constructed to identify the expression of pCHK2-Thr68 and pCDC25C-Ser216 in 292 female breast cancer patients. The relationship among protein expression, clinicopathological factors (e.g., human epidermal growth factor receptor 2 (HER 2), tumor size, tumor-node-metastasis (TNM) classification), and overall survival of the breast cancer tissues were analyzed using Pearson’s χ-square (χ2) test, Fisher’s exact test, multivariate logistic regression and Kaplan–Meier survival analysis. Significantly higher expressions of pCHK2-Thr68 and pCDC25C-Ser216 were observed in the nucleus of the breast cancer cells compared to the paracancerous tissue (pCHK2-Thr68, 20.38% vs. 0%; pCDC25C-Ser216, 82.26% vs. 24.24%). The expression of pCHK2-Thr68 and pCDC25C-Ser216 in breast cancer showed a positive linear correlation (p = 0.026). High expression of pCHK2-Thr68 was associated with decreased patient survival (p = 0.001), but was not an independent prognostic factor. Our results suggest that pCHK2-Thr68 and pCDC25C-Ser216 play important roles in breast cancer and may be potential treatment targets. View Full-Text
Keywords: pCHK2-Thr68; pCDC25C-Ser216; immunohistochemistry; breast cancer; genomic instability pCHK2-Thr68; pCDC25C-Ser216; immunohistochemistry; breast cancer; genomic instability

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Jiang, H.; Wang, B.; Zhang, F.; Qian, Y.; Chuang, C.-C.; Ying, M.; Wang, Y.; Zuo, L. The Expression and Clinical Outcome of pCHK2-Thr68 and pCDC25C-Ser216 in Breast Cancer. Int. J. Mol. Sci. 2016, 17, 1803.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top